Clinical trial NCT03353428: Intervention of Engineered Immune Effector T Cells Against Lung Cancer
Official title: Interventional Treatment of Lung Cancer (LC) With LC Specific Immune Lymphocytes (LC-CTLs)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Lung Cancer
NSCLC
Keywords: Lung cancer
Cytotoxic lymphocyte
LC-CTL
NSCLC
Lead sponsor: Shenzhen Geno-Immune Medical Institute
Sponsor class: OTHER
First posted: 2017-11-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the safety of lung cancer specific cytotoxic lymphocytes (LC-CTLs). The secondary objectives are to evaluate the rate of successful LC-CTLs generation in vitro and determine the anti-lung cancer efficacy.

Detailed description: Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). Worldwide in 2012, lung cancer occurred in 1.8 million people and resulted in 1.6 million deaths. Common treatments include surgery, chemotherapy, and radiotherapy.

Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific viral antigens has proven to be effective. Here, the investigators aim to evaluate the safety and efficacy of multiple infusions of lung cancer specific cytotoxic T lymphocytes cells in patients.

Eligibility criteria: Inclusion Criteria:

1. Written, informed consent obtained prior to any study-specific procedures.
2. Age older than 18 years.
3. Patients with refractory, relapsed, metastatic, advanced lung cancer confirmed by histology and biopsy.
4. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
5. Expected survival ≥ 12 weeks.
6. Not pregnant, and on appropriate birth control if of childbearing potential.
7. Initial hematopoietic reconstitution with

   * neutrophils (ANC) ≥ 1,000/mm\^3;
   * platelet (PLT) ≥ 100,000/mm\^3.
8. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with

   * serum creatinine ≤ 2×ULN;
   * serum bilirubin ≤ 2×ULN;
   * AST/ALT ≤ 2×ULN;
   * ALKP ≤ 5×ULN;
   * serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome.
9. Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) test were negative.

Exclusion Criteria:

1. Have occurred in 5 years or are currently suffering from other cancers, except for cured cervical cancer, non-melanoma skin cancer and superficial bladder cancer.
2. Previous exposure to mouse CEA antibody.
3. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.
4. Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations).
5. Pregnant or lactating females.
6. Inadequate bone marrow function with

   * absolute neutrophil count \< 1,000/mm\^3;
   * platelet count \< 100,000/mm\^3;
   * Hb \< 9 g/dL.
7. Inadequate liver and renal function with

   * serum (total) bilirubin \> 1.5 x ULN;
   * AST \& ALT \> 2.5 x ULN (\> 5 x ULN in patients with liver metastases);
   * alkaline phosphatase \> 2.5 x ULN;
   * serum creatinine \>2.0 mg/dl (\> 177 μmol/L);
   * urine dipstick for protein uria should be \< 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate \< 1 g of protein/24 hr.
8. Serious active infection requiring i.v. antibiotics at during screening.
9. Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive.

Primary outcomes:
measure: Safety of LC-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events
timeFrame: 3 months
Secondary outcomes:
measure: Functional analyses of LC-CTLs in vitro
timeFrame: 2 weeks
measure: Anti-tumor effects
timeFrame: 1 year
Other outcomes:
Locations:
city: Shenzhen
country: China
facility: Shenzhen Geno-immune Medical Institute
state: Guangdong
Study officials:
affiliation: Shenzhen Geno-Immune Medical Institute
name: Lung-Ji Chang, PhD
role: PRINCIPAL_INVESTIGATOR
References: